Market Overview:
The global common drugs use in ophthalmology market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth of this market is mainly attributed to the increasing prevalence of eye disorders, rising geriatric population, and technological advancements in ophthalmic devices. The global common drugs use in ophthalmology market by type is segmented into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, andanti-VEGF agents. The anti-inflammatory drug segment accounted for the largest share of the global common drug use in ophthalmology market by type in 2017 and is projected to grow at a CAGR of 6.8% during the forecast period from 2018 to 2030. This growth can be attributed to factors such as an increase in awareness about various inflammatory eye diseases and their treatments among patients as well as healthcare professionals; growing incidence rates of uveitis (inflammation inside the eye), iritis (inflammation around iris), conjunctivitis (pink eye), dry eyes syndrome; and rising demand for combination therapies that include multiple types of medications for better patient outcomes.
Product Definition:
Some common drugs used in ophthalmology are antibiotics, anti-inflammatory medications, and steroids. These drugs can be used to treat a variety of eye conditions, such as infections, uveitis, and glaucoma. The importance of using these drugs in ophthalmology is that they can help to improve the patient's symptoms and may help to prevent further damage to the eye.
Anti-inflammatory Drugs:
Anti-inflammatory drugs are the drugs that reduce inflammation by decreasing the production of cytokines. Cytokines are proteins that act as messengers between cells in the immune system and help them to communicate. The most common drug used for anti-inflammatory effect is called as corticosteroid. They work by decreasing amount of cytokine produced, thus reducing inflammation.
Anti-infective Drugs:
Anti-infective drugs are used to treat bacterial, fungal or viral infections. The anti-infective drugs market is segmented on the basis of drug class into Antibiotics, Antivirals and Anti-fungal agents. These products act against microorganisms by inhibiting their growth or killing them and this effect is achieved through different mechanisms such as disruption of their cell wall or affecting essential nutrients in the cell.
Application Insights:
Dry eye was the most prominent application segment in the global common drugs use in ophthalmology market, accounting for over 30.0% share of the total revenue in 2017. The increasing prevalence of dry eye syndrome is expected to be a major factor driving demand over the forecast period. According to an article published by NCBI, around 40% of population suffers from some form of dry eye and it is more prevalent among women as compared men due to hormonal fluctuations that lead to increased sensitivity towards irritation on eyes.
Glaucoma is anticipated to be one of the fastest-growing segments during forecast years owing to factors such as rising number Glaucoma patients.
Regional Analysis:
In 2017, North America dominated the global market owing to the presence of a large number of key players and well-established healthcare infrastructure. Moreover, an increase in R&D activities by major companies is also contributing towards growth in this region. For instance, Fovista Health (acquired by Alcon) was developing eye drop formulations for various diseases such as dengue fever and rosevein allergy using its proprietary technology.
Asia Pacific is expected to grow at a lucrative rate over the forecast period due to factors such as increasing prevalence of ophthalmic disorders coupled with rising disposable income & consumer awareness about early diagnosis & treatment options available for common diseases such as glaucoma and infection/inflammation affecting vision. In addition, high unmet clinical needs along with growing investment by governments & private entities are some other factors driving growth in this region.
Growth Factors:
- Increasing prevalence of eye diseases and disorders: The increasing prevalence of various eye diseases and disorders is one of the key growth drivers for the global common drugs use in ophthalmology market. According to a study by the World Health Organization (WHO), over 285 million people were affected by visual impairment in 2015, out of which 246 million were cases of uncorrected refractive errors. This number is expected to increase significantly in the coming years due to the rising population and aging demographics.
- Growing awareness about eye health: There has been a significant rise in awareness about eye health in recent years, owing to various campaigns launched by government organizations as well as non-profit organizations worldwide. This is resulting in an increased demand for ophthalmic drugs and devices, thereby driving market growth.
- Technological advancements: The advent of new technologies such as laser surgery has revolutionized the field of ophthalmology, leading to better diagnosis and treatment outcomes for patients suffering from various eye conditions or disorders. This is resulting in an increased demand for common drugs used specifically for treating different types of ocular diseases or conditions, thereby propelling market growth further.
Scope Of The Report
Report Attributes
Report Details
Report Title
Common Drugs Use in Ophthalmology Market Research Report
By Type
Anti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, Anti-VEGF Agents, Others
By Application
Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Others
By Companies
Pfizer, Novartis, Bausch Health, Fresenius, Teva Pharmaceutical, Allergan, Mylan, Santen Pharmaceutical, Takeda, Johnson & Johnson, APOTEX, GE Medical, Jamp Pharma, Senju Pharmaceutical, Chongqing Chemical & Pharmaceutical Holding (Group) Company, Sun Pharmaceutical, Taj Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Common Drugs Use in Ophthalmology Market Report Segments:
The global Common Drugs Use in Ophthalmology market is segmented on the basis of:
Types
Anti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, Anti-VEGF Agents, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Bausch Health
- Fresenius
- Teva Pharmaceutical
- Allergan
- Mylan
- Santen Pharmaceutical
- Takeda
- Johnson & Johnson
- APOTEX
- GE Medical
- Jamp Pharma
- Senju Pharmaceutical
- Chongqing Chemical & Pharmaceutical Holding (Group) Company
- Sun Pharmaceutical
- Taj Pharmaceuticals
Highlights of The Common Drugs Use in Ophthalmology Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-inflammatory Drugs
- Anti-infective Drugs
- Anti-glaucoma Drugs
- Anti-allergy Drugs
- Anti-VEGF Agents
- Others
- By Application:
- Dry Eye
- Glaucoma
- Infection/Inflammation
- Retinal Disorders
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Common Drugs Use in Ophthalmology Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Common drugs used in ophthalmology include antibiotics, painkillers, and anti-inflammatory medications.
Some of the key players operating in the common drugs use in ophthalmology market are Pfizer, Novartis, Bausch Health, Fresenius, Teva Pharmaceutical, Allergan, Mylan, Santen Pharmaceutical, Takeda, Johnson & Johnson, APOTEX, GE Medical, Jamp Pharma, Senju Pharmaceutical, Chongqing Chemical & Pharmaceutical Holding (Group) Company, Sun Pharmaceutical, Taj Pharmaceuticals.
The common drugs use in ophthalmology market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Common Drugs Use in Ophthalmology Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Common Drugs Use in Ophthalmology Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Common Drugs Use in Ophthalmology Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Common Drugs Use in Ophthalmology Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Common Drugs Use in Ophthalmology Market Size & Forecast, 2018-2028
4.5.1 Common Drugs Use in Ophthalmology Market Size and Y-o-Y Growth
4.5.2 Common Drugs Use in Ophthalmology Market Absolute $ Opportunity
Chapter 5 Global Common Drugs Use in Ophthalmology Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Common Drugs Use in Ophthalmology Market Size Forecast by Type
5.2.1 Anti-inflammatory Drugs
5.2.2 Anti-infective Drugs
5.2.3 Anti-glaucoma Drugs
5.2.4 Anti-allergy Drugs
5.2.5 Anti-VEGF Agents
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Common Drugs Use in Ophthalmology Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Common Drugs Use in Ophthalmology Market Size Forecast by Applications
6.2.1 Dry Eye
6.2.2 Glaucoma
6.2.3 Infection/Inflammation
6.2.4 Retinal Disorders
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Common Drugs Use in Ophthalmology Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Common Drugs Use in Ophthalmology Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Common Drugs Use in Ophthalmology Analysis and Forecast
9.1 Introduction
9.2 North America Common Drugs Use in Ophthalmology Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Common Drugs Use in Ophthalmology Market Size Forecast by Type
9.6.1 Anti-inflammatory Drugs
9.6.2 Anti-infective Drugs
9.6.3 Anti-glaucoma Drugs
9.6.4 Anti-allergy Drugs
9.6.5 Anti-VEGF Agents
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Common Drugs Use in Ophthalmology Market Size Forecast by Applications
9.10.1 Dry Eye
9.10.2 Glaucoma
9.10.3 Infection/Inflammation
9.10.4 Retinal Disorders
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Common Drugs Use in Ophthalmology Analysis and Forecast
10.1 Introduction
10.2 Europe Common Drugs Use in Ophthalmology Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Common Drugs Use in Ophthalmology Market Size Forecast by Type
10.6.1 Anti-inflammatory Drugs
10.6.2 Anti-infective Drugs
10.6.3 Anti-glaucoma Drugs
10.6.4 Anti-allergy Drugs
10.6.5 Anti-VEGF Agents
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Common Drugs Use in Ophthalmology Market Size Forecast by Applications
10.10.1 Dry Eye
10.10.2 Glaucoma
10.10.3 Infection/Inflammation
10.10.4 Retinal Disorders
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Common Drugs Use in Ophthalmology Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Common Drugs Use in Ophthalmology Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Common Drugs Use in Ophthalmology Market Size Forecast by Type
11.6.1 Anti-inflammatory Drugs
11.6.2 Anti-infective Drugs
11.6.3 Anti-glaucoma Drugs
11.6.4 Anti-allergy Drugs
11.6.5 Anti-VEGF Agents
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Common Drugs Use in Ophthalmology Market Size Forecast by Applications
11.10.1 Dry Eye
11.10.2 Glaucoma
11.10.3 Infection/Inflammation
11.10.4 Retinal Disorders
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Common Drugs Use in Ophthalmology Analysis and Forecast
12.1 Introduction
12.2 Latin America Common Drugs Use in Ophthalmology Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Common Drugs Use in Ophthalmology Market Size Forecast by Type
12.6.1 Anti-inflammatory Drugs
12.6.2 Anti-infective Drugs
12.6.3 Anti-glaucoma Drugs
12.6.4 Anti-allergy Drugs
12.6.5 Anti-VEGF Agents
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Common Drugs Use in Ophthalmology Market Size Forecast by Applications
12.10.1 Dry Eye
12.10.2 Glaucoma
12.10.3 Infection/Inflammation
12.10.4 Retinal Disorders
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Common Drugs Use in Ophthalmology Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Common Drugs Use in Ophthalmology Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Common Drugs Use in Ophthalmology Market Size Forecast by Type
13.6.1 Anti-inflammatory Drugs
13.6.2 Anti-infective Drugs
13.6.3 Anti-glaucoma Drugs
13.6.4 Anti-allergy Drugs
13.6.5 Anti-VEGF Agents
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Common Drugs Use in Ophthalmology Market Size Forecast by Applications
13.10.1 Dry Eye
13.10.2 Glaucoma
13.10.3 Infection/Inflammation
13.10.4 Retinal Disorders
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Common Drugs Use in Ophthalmology Market: Competitive Dashboard
14.2 Global Common Drugs Use in Ophthalmology Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Bausch Health
14.3.4 Fresenius
14.3.5 Teva Pharmaceutical
14.3.6 Allergan
14.3.7 Mylan
14.3.8 Santen Pharmaceutical
14.3.9 Takeda
14.3.10 Johnson & Johnson
14.3.11 APOTEX
14.3.12 GE Medical
14.3.13 Jamp Pharma
14.3.14 Senju Pharmaceutical
14.3.15 Chongqing Chemical & Pharmaceutical Holding (Group) Company
14.3.16 Sun Pharmaceutical
14.3.17 Taj Pharmaceuticals
